Moderna (MRNA) put mRNA technology on the map, however, this technology has not yet proven itself convincingly in clinical trials. The concept of making your own body behave like a drug manufacturing engine is interesting, but it has its hurdles. One hurdle is the body's own immune system, which may reject the mRNA; the other is whether the technology will produce enough proteins to make a difference - with the human body, you never know what will trigger a cascade of unpredictable events that could foil the "best laid plans of men," however smart. Delivery into cells is another issue. Everything always boils down to human trials - and here, Moderna is not there yet.
Most of the biotech investing rules I follow tell me Moderna is an absolute avoid. One, a $12bn market valuation based on a pipeline of near 20 candidates. These are based on a single all-curing drug platform. Not a single drug candidate is beyond phase 2. Two, the current price of the one-year old IPO is at 52-week and all time highs based on a fear and hope around a sudden pandemic like coronavirus. Three, a corollary of point one, there is little phase 2 efficacy data anywhere, therefore the platform, however promising, is absolutely unproven. However, on the other hand, another critical business rule I also follow is "follow the cash," and this early stage biopharma has $2bn of it. This is more cash than the entire current market cap of a company like Amarin (AMRN) with an approved and blockbuster potential product.
In order to understand this anomaly, I looked into the science behind the company, because the valuation of a pre-market pre-approval stage biopharma is mostly based on the science. And the science does look promising.
First, let us understand that the company says that mRNA-based therapeutic protein synthesis is the next step to recombinant protein technology, which has spawned an industry worth over $200bn. However, recombinant technology cannot create certain major types of proteins - intracellular and membrane proteins which represent as much as two-thirds of the proteins in humans. This is a major part of what mRNA technology can do.
There are various competitive advantages to mRNA over recombinance - for one, since the proteins are made naturally, there's less chance of rejection and immunogenicity. Another advantage, as the company says, "A vast number of potential mRNA medicines can be developed, therefore, with only minor changes to the underlying chemical structure of the molecule or manufacturing processes, a significant advantage over small molecule or protein therapeutics."
Moderna was founded in 2010 and IPO-ed in late 2018. Reading through the 10-K, what struck me was that there's a huge number of programs, all of them early stages, each demonstrating, to some extent, the development of critical antibodies upon using the drug candidate. However, instead of developing any particular program to fruition, including BLA and approval, this company focuses on advancing the entire pipeline at the same time.
Here's a snapshot of the pipeline:
Source
Next, let me present a set of 6 slides, each for one of the modalities above, which shows the latest available trial data for that drug candidate:-
Source - 10-K
Now, we have multiple programs progressing through phase 2 - which is really the datapoint that first gets us interested (or not) in a company. Then, just today, we read about the company's plans to start a phase 3 trial "soon." However, like we said, we still couldn't find enough that could justify this huge $11.8bn valuation. I mean, the science is good, in theory, but this sort of high-grade technology has so many pitfalls it really doesn't make sense to have too much expectation until we see phase 3 data.
The above 6 slides basically show that in the lab and in primates and in healthy subjects, there's constructive antibody activity on dosing with these mRNA medicines. Some of the measures of these activities are promising, for example, for mRNA-1944, "participants had measured antibody levels exceeding the levels of antibody expected to be protective against chikungunya infection (> 1 g/mL) following a single dose, with the middle and high doses projected to maintain antibody levels above protective levels for at least 16 weeks." But this was a phase 1 study in healthy volunteers, and while promising, like I said, this alone does not justify the valuation.
Sometimes, companies like these justify their valuations on the basis of their founders, or the founding technology; Juno comes to mind. Again, nothing like that was clearly apparent to me on reading either the 10-K or the Corporate Presentation. Besides a lot of basic and advanced genetic science, I could not figure out who is behind the science; admittedly, though, MRNA does have a vast patent estate comprising more than 550 patents worldwide, applied for and granted.
A much better overview of the history of the science is found here. There are basically five key figures behind it; the original science was developed by University of Pennsylvania scientist Katalin Karik, but her startup didn't go anywhere directly. "Later, in 2010 Harvard University scientist Derrick Rossi used modified mRNA to encode proteins that reprogrammed adult cells into embryonic-like stem cells. Harvard cardiovascular scientist Kenneth Chien, now at the Karolinska Institute, and Massachusetts Institute of Technologys famed serial entrepreneur Robert Langer spotted mRNAs therapeutic potential and joined Rossi in pitching a stem cell company to the venture capital firm Flagship Pioneering." This led to Moderna.
In recent times, under the coronavirus pandemic, Moderna has suppressed the rest of its pipeline and is focusing almost entirely on mRNA-1273, its candidate for treating COVID-19. Although mRNA can in theory target multiple types of diseases, vaccines are still their easiest application, since "the mRNA needs to produce only a small amount of protein for the vaccine to work, and setting off the bodys RNA immune sensors a little wont hurt." The company already had multiple viral vaccine targets under development, including one on MERS-COV in the lab, so it is understandable that a little tweak could set things off in coronavirus targeting.
From its press release, the latest that is happening in this regard is
On March 27, 2020, the NIH announced that Emory University in Atlanta will begin enrolling healthy adult volunteers ages 18 to 55 years in the NIH-led Phase 1 study of mRNA-1273.
According to a PR dated 4/7/2020, Moderna will host a virtual Vaccines Day for analysts and investors on 4/14/2020. The Vaccines Day will include presentations from Stphane Bancel, Chief Executive Officer, Tal Zaks, Chief Medical Officer, and key opinion leaders with a focus on mRNA vaccines and the Companys core prophylactic vaccines modality.
According to another PR dated 4/8/2020, Lorence Kim, M.D., the company's Chief Financial Officer, will participate in the 19th Annual Needham Healthcare Conference on 4/15/2020.
Currently, everything in this $12bn behemoth hinges around producing a working vaccine for SARS-COV-2. There are pitfalls - efficacy, timeline, positioning, market - that could determine how it all works out. Success or failure here could determine what happens to the company as a whole, because the market seems to be in an over-expectant mode right now.
In 2018, when the company IPO-ed, CEO Bancel said This is a 20-year job...We believe we are just starting. It seems to this author that $12bn is just a little too much to start with for something that may be promising, but still unproven. The science looks good - although there's a lot of secrecy behind it as of now - so if these prices go down for whatever reason, I would be much more interested. The company's vast and diverse collaborations - with AstraZeneca (NYSE:AZN), Merck (NYSE:MRK) and others - does build confidence that big pharma is looking at it favorably.
Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.
That means that when the catalyst comes that will make or break a stock, we've positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: I own AMRN.
See more here:
Moderna: A $12 Billion Brand Built On Hope And mRNA - Seeking Alpha
- Cutting-Edge Exercise Science Takes International Stage at ACSM Conference [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Stem Cell Therapy for Hip Injuries and Arthritis ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Penn Medicine News: A New Way to Make Reprogrammed Stem Cells [Last Updated On: August 26th, 2014] [Originally Added On: August 26th, 2014]
- Penn Medicine News: Male Pattern Balding May Be Due to ... [Last Updated On: August 26th, 2014] [Originally Added On: August 26th, 2014]
- University of Pennsylvania | The Stem Cell Blog [Last Updated On: September 1st, 2014] [Originally Added On: September 1st, 2014]
- Bloodless Stem Cell Transplant Program at Pennsylvania ... [Last Updated On: September 5th, 2014] [Originally Added On: September 5th, 2014]
- Postdoctoral Fellow, Cancer and Stem Cell Biology ... [Last Updated On: September 6th, 2014] [Originally Added On: September 6th, 2014]
- Philadelphia Pennsylvania Stem Cell Research ... [Last Updated On: September 21st, 2014] [Originally Added On: September 21st, 2014]
- Questions and Answers on Stem Cell Research | Pennsylvania ... [Last Updated On: October 3rd, 2014] [Originally Added On: October 3rd, 2014]
- Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied [Last Updated On: October 15th, 2014] [Originally Added On: October 15th, 2014]
- Stem Cell Therapy Pennsylvania | Stem Cell Treatments [Last Updated On: October 15th, 2014] [Originally Added On: October 15th, 2014]
- Sangamo BioSciences ZFP Therapeutic Program in HIV/AIDS Featured at Three Major Scientific Conferences in October 2014 [Last Updated On: October 16th, 2014] [Originally Added On: October 16th, 2014]
- Immune Therapy Induces Remission for Many With a Tough-to-Treat Blood Cancer [Last Updated On: October 18th, 2014] [Originally Added On: October 18th, 2014]
- Stem Cell and Xenograft Core: Biomedical Research Core ... [Last Updated On: October 27th, 2014] [Originally Added On: October 27th, 2014]
- First Study to Convert Adult Human Cells to Hair-Follicle ... [Last Updated On: November 2nd, 2014] [Originally Added On: November 2nd, 2014]
- An Eclectic Path to Precision Medicine [Last Updated On: November 25th, 2014] [Originally Added On: November 25th, 2014]
- Cyanide killed hospital employee, official says [Last Updated On: November 29th, 2014] [Originally Added On: November 29th, 2014]
- Penn Medicine Researchers Announce Latest Results of Investigational Cellular Therapy CTL019 [Last Updated On: December 8th, 2014] [Originally Added On: December 8th, 2014]
- Stemiotics Licenses Modified RNA for Cell Reprogramming [Last Updated On: December 22nd, 2014] [Originally Added On: December 22nd, 2014]
- MD Anderson Names Hwu as Head of Cancer Medicine [Last Updated On: February 26th, 2015] [Originally Added On: February 26th, 2015]
- Penn vet team points to new colon cancer culprit [Last Updated On: March 16th, 2015] [Originally Added On: March 16th, 2015]
- Knee Stem Cell Therapy and Platelet Procedures Pittsburgh ... [Last Updated On: July 2nd, 2015] [Originally Added On: July 2nd, 2015]
- Tissue Niches & Resident Stem Cells in Adult Epithelia - GRC [Last Updated On: August 26th, 2016] [Originally Added On: August 26th, 2016]
- 2016 Scientific Program [Last Updated On: December 4th, 2016] [Originally Added On: December 4th, 2016]
- La Jolla Light News Nuggets: July 27 - La Jolla Light [Last Updated On: July 30th, 2017] [Originally Added On: July 30th, 2017]
- Rare leukemia targeted by modifying patients' immune cells - New Haven Register [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- Campus achievement - Sunbury Daily Item [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- COLUMN: Startling statistics concerning drug deaths in rural communities - Meadville Tribune [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
- Tucson's Calimmune to be acquired by Australian drug giant - Arizona Daily Star [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Hair Regrowth using Stem Cells | Ashley and Martin [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Bone Marrow Protein May Be Target for Improving Stem Cell Transplants - Penn: Office of University Communications [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young ... - GlobeNewswire (press release) [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Meetings [Last Updated On: October 8th, 2017] [Originally Added On: October 8th, 2017]
- Stem Cell Therapy in Conewago Township, Pennsylvania [Last Updated On: July 19th, 2018] [Originally Added On: July 19th, 2018]
- Stem Cell Treatment - Philadelphia Bala Cynwyd, PA: World ... [Last Updated On: August 13th, 2018] [Originally Added On: August 13th, 2018]
- About Penn's IRM - Institute for Regenerative Medicine [Last Updated On: September 16th, 2018] [Originally Added On: September 16th, 2018]
- Regrowing dental tissue with stem cells from baby teeth ... [Last Updated On: October 2nd, 2018] [Originally Added On: October 2nd, 2018]
- Stem Cell Therapy in York County, Pennsylvania [Last Updated On: October 8th, 2018] [Originally Added On: October 8th, 2018]
- Pittsburgh, Pennsylvania - Stem Cells Transplant Institute [Last Updated On: November 18th, 2018] [Originally Added On: November 18th, 2018]
- Cells Weekly October 11, 2015 - stemcellassays.com [Last Updated On: February 5th, 2019] [Originally Added On: February 5th, 2019]
- Lung Institute Review | Do Stem Cell Treatments Work? [Last Updated On: April 21st, 2019] [Originally Added On: April 21st, 2019]
- Stem Cell Therapy in Lancaster Pennsylvania | Stem Cell ... [Last Updated On: April 24th, 2019] [Originally Added On: April 24th, 2019]
- Cary Ortho Utilizes Bone Marrow Stem Cells for General ... [Last Updated On: May 12th, 2019] [Originally Added On: May 12th, 2019]
- Robert Lanza - Wikipedia [Last Updated On: May 12th, 2019] [Originally Added On: May 12th, 2019]
- University of Pennsylvania || Cell and Molecular Biology ... [Last Updated On: September 7th, 2019] [Originally Added On: September 7th, 2019]
- AI uncovers genes linked to heart failure - FierceBiotech [Last Updated On: September 27th, 2019] [Originally Added On: September 27th, 2019]
- Reviewing Madrigal Pharmaceuticals Inc. (MDGL)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly [Last Updated On: October 30th, 2019] [Originally Added On: October 30th, 2019]
- Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy - Seeking Alpha [Last Updated On: October 30th, 2019] [Originally Added On: October 30th, 2019]
- These Israeli Companies Are Finding Innovative Ways To Improve Diabetes Care, Treatment | Health News - NoCamels - Israeli Innovation News [Last Updated On: November 16th, 2019] [Originally Added On: November 16th, 2019]
- Reviewing BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - Mitchell Messenger [Last Updated On: November 16th, 2019] [Originally Added On: November 16th, 2019]
- Critical Review: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - NCTY News [Last Updated On: November 16th, 2019] [Originally Added On: November 16th, 2019]
- Head to Head Survey: BioRestorative Therapies (OTCMKTS:BRTX) & Livongo Health (OTCMKTS:LVGO) - Mitchell Messenger [Last Updated On: December 1st, 2019] [Originally Added On: December 1st, 2019]
- 253 miles in 4 hours: A Syracuse mans race for a lung transplant, and the angel who helped him - syracuse.com [Last Updated On: December 1st, 2019] [Originally Added On: December 1st, 2019]
- Trevena Inc. (TRVN)'s Financial Results Comparing With VistaGen Therapeutics Inc. (NASDAQ:VTGN) - The Broch Herald [Last Updated On: December 9th, 2019] [Originally Added On: December 9th, 2019]
- 2019: The year gene therapy came of age - Jamaica Observer [Last Updated On: December 9th, 2019] [Originally Added On: December 9th, 2019]
- What a time to be alive: Reproductive breakthroughs of the 2010s that changed life as we know it - FOX 10 News Phoenix [Last Updated On: January 3rd, 2020] [Originally Added On: January 3rd, 2020]
- The potential use of CRISPR to treat disease is gaining momentum - BioNews [Last Updated On: January 16th, 2020] [Originally Added On: January 16th, 2020]
- Why Choose Us - Pennsylvania Stem Cell Center [Last Updated On: April 10th, 2020] [Originally Added On: April 10th, 2020]
- Pregnant and positive | Scientists look for COVID-19 immunity in the womb - WHAS11.com [Last Updated On: April 23rd, 2020] [Originally Added On: April 23rd, 2020]
- Chinas scientists accused of playing God by creating monstrous cloned apes and primates with human organs - The Sun [Last Updated On: May 11th, 2020] [Originally Added On: May 11th, 2020]
- Vasomune Therapeutics Announces Clinical and Scientific Advisory Board - BioSpace [Last Updated On: May 11th, 2020] [Originally Added On: May 11th, 2020]
- Stem Cell Treatment Bala Cynwyd | Stem Cell Therapy ... [Last Updated On: May 25th, 2020] [Originally Added On: May 25th, 2020]
- Orthopedics - Pennsylvania Stem Cell Center [Last Updated On: May 25th, 2020] [Originally Added On: May 25th, 2020]
- Coming Together to Solve COVID-19 Mysteries | University of Pennsylvania Almanac - UPENN Almanac [Last Updated On: June 4th, 2020] [Originally Added On: June 4th, 2020]
- Eradicating balding a step closer with new procedure in the cross hairs - The New Daily [Last Updated On: June 4th, 2020] [Originally Added On: June 4th, 2020]
- Are very long-lived trees immortal and what can they teach humans? - ABC News [Last Updated On: August 10th, 2020] [Originally Added On: August 10th, 2020]
- T cells, B cells and the range of the human bodys immune response A simple decoder - ThePrint [Last Updated On: August 10th, 2020] [Originally Added On: August 10th, 2020]
- Dr. Andreas Sauerbrey: The right orthopaedic diagnosis is essential to proper care - Sky Hi News [Last Updated On: September 12th, 2020] [Originally Added On: September 12th, 2020]
- The story of mRNA: From a loose idea to a tool that may help curb Covid - STAT [Last Updated On: November 11th, 2020] [Originally Added On: November 11th, 2020]
- 'Benjamin Button' discovery could reverse ageing process - Queensland Times [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Penn researchers find a way through the labyrinth keeping CAR-T from solid tumors - Endpoints News [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Newly Discovered Glycosylated RNA Is All Over Cells: Study - The Scientist [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Bispecific Antibodies Wage a Two-Pronged Attack on Tumors - Curetoday.com [Last Updated On: June 23rd, 2021] [Originally Added On: June 23rd, 2021]
- Millions in federal money flowed to tissue bank that collected fetal 'heart, gonads, legs, brain': report - Fox News [Last Updated On: August 5th, 2021] [Originally Added On: August 5th, 2021]
- People and places at Penn | Penn Today - Penn Today - Penn Today [Last Updated On: August 18th, 2021] [Originally Added On: August 18th, 2021]
- NIH, FDA and 15 private organizations join forces to increase effective gene therapies for rare diseases - National Institutes of Health [Last Updated On: October 28th, 2021] [Originally Added On: October 28th, 2021]
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases - FDA.gov [Last Updated On: October 28th, 2021] [Originally Added On: October 28th, 2021]
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Stockhouse [Last Updated On: October 28th, 2021] [Originally Added On: October 28th, 2021]
- Penn State recipients of Whitaker Center's Women of Impact 2021 awards unite through research - The Daily Collegian Online [Last Updated On: March 25th, 2022] [Originally Added On: March 25th, 2022]
- ChristianaCare and The Wistar Institute Advance Partnership With New Cancer Research Strategies - ChristianaCare News [Last Updated On: March 25th, 2022] [Originally Added On: March 25th, 2022]